Newborn Metabolic Screening Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Newborn Metabolic Screening Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Global New-Born Metabolic Screening Market to Reach US$ 636.95 Mn by 2031, Growing at a CAGR of 8.9%. Projected Market Surge from US$ 350.68 Mn in 2024 to US$ 636.95 Mn by 2031

The global new-born metabolic screening market, valued at US$ 350.68 Mn in 2024, is poised for substantial growth over the next decade. Market forecasts project the sector will reach approximately US$ 636.95 Mn by 2031, with a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031. This significant expansion is driven by the increasing prevalence of metabolic disorders in new-borns and the rising demand for early diagnosis and treatment.

Increasing Demand Due to Rising Prevalence of Metabolic Disorders

The rising prevalence of metabolic disorders in new-borns, including conditions such as sickle cell disease, maple syrup urine disease, galactosemia, phenylketonuria, and cystic fibrosis, is a major driver for the new-born metabolic screening market. Early detection of these disorders is crucial, as it significantly improves treatment outcomes and reduces the risk of severe complications.

New-born screening has advanced from routine blood and urine tests to more comprehensive and complex systems capable of diagnosing over 50 different disorders. This evolution has led to a surge in the adoption of these screening tests worldwide.

Government and Private Initiatives Bolstering Market Growth

Government and private organization initiatives to implement metabolic screening programs are also propelling market growth. For instance, India’s Ayushman Bharat program, one of the largest people-centric health initiatives, aims to improve child and maternal health. Such programs are instrumental as countries strive to achieve universal health coverage and enhance reproductive, child, maternal, new-born, and adolescent health outcomes.

Technological Advancements and Increased Awareness

Technological advancements, such as the development of mass spectrometers and oximeters with enhanced performance, are supporting market sales. These innovations have made it possible to detect multiple metabolic disorders using a single cassette, thus reducing the burden of multiple tests on new-borns and their families.

Growing awareness about metabolic disorders among parents, driven by organizations like the WHO, CDC, and the Healthy New-born Network, is also playing a critical role in market growth. These organizations educate parents about potential problems and the importance of early testing, which helps prevent infant mortality.

Rising New-Born Population and Improved Screening Options

A primary factor contributing to market growth is the rising number of new-borns globally. Coupled with the increasing prevalence of metabolic diseases during the neonatal period, this necessitates better screening options. Lab-based integrated new diagnostics have significantly impacted patient survival rates by speeding up the diagnosis of metabolic issues, thereby enhancing treatment outcomes.

Governments are increasingly providing funding for new-born screening programs to combat the growing burden of metabolic diseases. Companies entering this market focus on developing tests with high medical value to offer more personalized medicine, expected to be highly profitable.

Challenges in Underdeveloped Countries

Despite the positive outlook, the market faces several challenges, particularly in underdeveloped countries. The lack of infrastructure improvements in the healthcare sector and a shortage of appropriately trained professionals are major impediments. For instance, in the Asia-Pacific region, new-born screening is still not extensively used due to high population densities, low and intermediate income levels, and inadequate healthcare systems.

Moreover, the lack of uniformity in new-born screening policies and procedures globally, coupled with a high rate of false positive and false negative test results, poses significant challenges. The decision-making process of healthcare practitioners is further hampered by a lack of information on the long-term effects of new disorders and a scarcity of follow-up data for screening conditions.

Key Market Players:
• PerkinElmer
• Bio-Rad Laboratories
• Trivitron Healthcare Private Limited
• BioMedomics, Inc.
• Luminex Corporation
• MP BIOMEDICALS
• Synergy Medical Systems LLP
• Agilent Technologies, Inc
• Thermo Fisher Scientific, Inc
• Zivak Technologies
• Covidien Plc
• AB Sciex LLC
• Waters Corp.
• Masimo Corp.
• Natus Medical Inc.


Global Newborn Metabolic Screening Market is Segmented as Below:

By Test:
• Galactosemia
• Sickle Cell Disease
• Cystic Fibrosis
• Toxoplasmosis
• Phenylketonuria (PKU)
• Methylmalonic Acidemia
• Maple Syrup Urine Disease (MSUD)
• Tyrosinemia
• Citrullinemia
• Medium Chain Acyl CoA Dehydrogenase (MCAD) Deficiency

By Sample:
• Blood
• Urine

By End User:
• Diagnostic Laboratories
• Specialty Clinics
• Hospital

By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.